Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation.

Autor: Leiter LA; Divisions of Endocrinology & Metabolism, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. Electronic address: leiterl@smh.ca., Shestakova MV; Endocrinology Research Centre, Moscow, Russian Federation; I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation., Trubitsyna NP; Endocrinology Research Centre, Moscow, Russian Federation., Piletič M; General Hospital, Novo Mesto, Novo Mesto, Slovenia., Satman I; Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.

Publikováno v: Diabetes research and clinical practice [Diabetes Res Clin Pract] 2016 Feb; Vol. 112, pp. 50-56. Date of Electronic Publication: 2015 Nov 23.

[Diabetes mellitus: renal osmoregulating function].

Autor: Natochin IuV, Shestakova MV, Kuznetsova AA, Klefortova II, Trubitsyna NP, Dedov II

Publikováno v: Terapevticheskii arkhiv [Ter Arkh] 2010; Vol. 82 (6), pp. 9-14.

[The angiotensin II inhibition escape phenomenon in patients with type 2 diabetes and diabetic nephropathy].

Autor: Shamkhlova MSh, Trubitsyna NP, Katsaia GV, Goncharov NP, Malysheva NM, Il'in AV, Nikankina LV, Koshel' LV, Shestakova MV

Publikováno v: Terapevticheskii arkhiv [Ter Arkh] 2008; Vol. 80 (1), pp. 49-52.